You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 8,415,311


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,415,311 protect, and when does it expire?

Patent 8,415,311 protects SOOLANTRA and is included in one NDA.

This patent has thirty-two patent family members in twenty-three countries.

Summary for Patent: 8,415,311
Title:Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s): Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee: Galderma S.A. (Cham, CH)
Application Number:13/310,633
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,415,311
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,415,311

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,415,311

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France03 05048Apr 24, 2003

International Family Members for US Patent 8,415,311

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1620113 ⤷  Sign Up C300756 Netherlands ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up CA 2015 00045 Denmark ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up PA2015033 Lithuania ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up 122015000079 Germany ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up 92915 Luxembourg ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up 56/2015 Austria ⤷  Sign Up
European Patent Office 1620113 ⤷  Sign Up 15C0069 France ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.